Polish pharmaceutical group Polpharma, which has recently acquired the Romanian drug manufacturer Biofarm in a deal valued at about EUR257 million, says that Romania is one of its strategic markets for growth in Central and Eastern Europe and announces it will continue to invest in the Romanian company’s development.